Literature DB >> 24775830

Valvular heart disease in hyperprolactinemic patients treated with low doses of cabergoline.

Juan G Córdoba-Soriano1, Cristina Lamas-Oliveira2, Víctor M Hidalgo-Olivares3, Antonia Tercero-Martínez3, Moisés Barambio-Ruíz3, Jesús Salas-Nieto3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24775830     DOI： 10.1016/j.rec.2012.10.016

Source DB:  PubMed          Journal:  Rev Esp Cardiol (Engl Ed)        ISSN： 1885-5857


× No keyword cloud information.
  2 in total

Review 1.  Screening for valve disease in patients with hyperprolactinaemia disorders prescribed cabergoline: a service evaluation and literature review.

Authors:  David Gamble; Rachel Fairley; Roderick Harvey; Colin Farman; Nathan Cantley; Stephen J Leslie
Journal:  Ther Adv Drug Saf       Date:  2017-04-25

2.  Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma.

Authors:  Shruti Khare; Anurag R Lila; Rishikesh Patil; Milind Phadke; Prafulla Kerkar; Tushar Bandgar; Nalini S Shah
Journal:  Indian J Endocrinol Metab       Date:  2017 Jan-Feb
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.